Cytotoxicity of alloantigen-specific CD4+and CD8+ CTLs against allogeneic Fas+/−and Fas−/− cells and autologous cells
| Donor . | Stimulator . | Phenotype . | Effector . | % Specific Lysis of Target Cells* . | ||||
|---|---|---|---|---|---|---|---|---|
| Allo (Fas+/−) LCL . | Allo (Fas−/−) LCL . | Allo (Fas+/−) E− . | Allo (Fas−/−) E− . | Auto LCL . | ||||
| M.Y. | Fas+/− | CD4 | Bulk #1-1 | 49.2 | 45.1 | 28.0 | 26.9 | 8.3 |
| Clone #1-1 | 68.3 | 64.9 | 43.7 | 48.1 | 2.7 | |||
| Clone #1-2 | 58.2 | 54.8 | 32.9 | 34.1 | 3.8 | |||
| CD8 | Clone #2-1 | 66.3 | 62.0 | 43.7 | 41.0 | 2.9 | ||
| Fas−/− | CD4 | Bulk #3-1 | 34.9 | 31.8 | 21.8 | 25.3 | 9.5 | |
| Clone #3-1 | 69.5 | 63.0 | 43.7 | 44.4 | 3.5 | |||
| Clone #3-2 | 53.2 | 57.6 | 34.5 | 32.0 | 3.4 | |||
| CD8 | Clone #4-1 | 68.7 | 69.6 | 45.2 | 40.1 | 3.9 | ||
| H.O. | Fas+/− | CD4 | Bulk #5-1 | 45.1 | 40.3 | 23.7 | 27.0 | 10.9 |
| Clone #5-1 | 56.6 | 53.0 | 32.1 | 35.5 | 4.4 | |||
| Clone #5-2 | 67.3 | 60.4 | 45.0 | 41.2 | 5.0 | |||
| CD8 | Clone #6-1 | 54.9 | 51.9 | 39.9 | 34.1 | 3.5 | ||
| Fas−/− | CD4 | Bulk #7-1 | 56.2 | 52.9 | 29.6 | 31.2 | 11.4 | |
| Clone #7-1 | 70.2 | 73.9 | 49.5 | 50.0 | 4.7 | |||
| Clone #7-2 | 62.7 | 68.9 | 34.1 | 38.0 | 6.3 | |||
| CD8 | Clone #8-1 | 54.1 | 50.3 | 34.7 | 35.7 | 3.0 | ||
| Donor . | Stimulator . | Phenotype . | Effector . | % Specific Lysis of Target Cells* . | ||||
|---|---|---|---|---|---|---|---|---|
| Allo (Fas+/−) LCL . | Allo (Fas−/−) LCL . | Allo (Fas+/−) E− . | Allo (Fas−/−) E− . | Auto LCL . | ||||
| M.Y. | Fas+/− | CD4 | Bulk #1-1 | 49.2 | 45.1 | 28.0 | 26.9 | 8.3 |
| Clone #1-1 | 68.3 | 64.9 | 43.7 | 48.1 | 2.7 | |||
| Clone #1-2 | 58.2 | 54.8 | 32.9 | 34.1 | 3.8 | |||
| CD8 | Clone #2-1 | 66.3 | 62.0 | 43.7 | 41.0 | 2.9 | ||
| Fas−/− | CD4 | Bulk #3-1 | 34.9 | 31.8 | 21.8 | 25.3 | 9.5 | |
| Clone #3-1 | 69.5 | 63.0 | 43.7 | 44.4 | 3.5 | |||
| Clone #3-2 | 53.2 | 57.6 | 34.5 | 32.0 | 3.4 | |||
| CD8 | Clone #4-1 | 68.7 | 69.6 | 45.2 | 40.1 | 3.9 | ||
| H.O. | Fas+/− | CD4 | Bulk #5-1 | 45.1 | 40.3 | 23.7 | 27.0 | 10.9 |
| Clone #5-1 | 56.6 | 53.0 | 32.1 | 35.5 | 4.4 | |||
| Clone #5-2 | 67.3 | 60.4 | 45.0 | 41.2 | 5.0 | |||
| CD8 | Clone #6-1 | 54.9 | 51.9 | 39.9 | 34.1 | 3.5 | ||
| Fas−/− | CD4 | Bulk #7-1 | 56.2 | 52.9 | 29.6 | 31.2 | 11.4 | |
| Clone #7-1 | 70.2 | 73.9 | 49.5 | 50.0 | 4.7 | |||
| Clone #7-2 | 62.7 | 68.9 | 34.1 | 38.0 | 6.3 | |||
| CD8 | Clone #8-1 | 54.1 | 50.3 | 34.7 | 35.7 | 3.0 | ||
Cytotoxicity of CD4+ and CD8+ CTL bulk lines and clones generated by stimulation of PBMCs isolated from unrelated donors with HLA class I and class II-mismatched Fas+/− or Fas−/− LCL against Fas+/− and Fas−/− target cells, as detailed in “Materials and methods.” Effector/target ratios were 5:1.